All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Metronomic Chemotherapy Represents Late Treatment Option for Some Patients With Metastatic Breast Cancer

March 6th 2023

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

March 5th 2023

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

March 4th 2023

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

Treatment in HR+ Early Breast Cancer May be Best Guided by Risk of Recurrence

March 4th 2023

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

March 4th 2023

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus

March 4th 2023

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

March 4th 2023

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer

March 3rd 2023

By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will benefit from therapy, enabling strategies with multiple pathway targets, and testing approaches earlier in the disease course.

ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm

March 3rd 2023

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

FDA Expands Abemaciclib Indication in HR+/HER2–, Node+, High-Risk Breast Cancer

March 3rd 2023

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions

March 3rd 2023

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

Fox Chase Researchers Receive $1 Million Grant to Develop Platform That Could Assist in Development of New Drugs

March 3rd 2023

John Karanicolas, PhD, co-leader of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, was recently awarded a $1 million grant from the W.M. Keck Foundation to develop a platform that could assist in the development of new drugs.

Miami Breast Cancer Conference Celebrates 40 Years

March 3rd 2023

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme

March 2nd 2023

The FDA has granted an orphan drug designation to Temferon for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Approval Sought for Cosibelimab in Metastatic or Locally Advanced CSCC

March 2nd 2023

A biologics license application seeking the approval of cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma has been accepted for filing by the FDA.

Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer

March 2nd 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

Mesenchymal Chondrosarcoma Is a Rare Sarcoma Subtype With Challenging Diagnosis

March 2nd 2023

R. Lor Randall, MD, FACS, discusses the presentation and diagnosis of mesenchymal chondrosarcomas, the role of HEY1-NCoA2 gene fusions in the disease, and potential treatment options for this rare subgroup of patients.

SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer Disparities

March 2nd 2023

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

Groundbreaking Grant to John Theurer Cancer Center Will Establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine

March 2nd 2023

The family of Mike and Patti Hennessy made a transformational gift in their memory to establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine.

Pragmatic Approaches to Cancer Management in the Absence of Randomized Trial Data

March 2nd 2023

Phase 3 randomized trials often fail to reasonably represent the actual population of patients seen in routine community practice.